Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future
Type 1 diabetes mellitus (T1DM) is a serious, chronic metabolic and autoimmune disease that affects millions globally. While insulin administration remains the most effective treatment, it is not a cure. Long-term therapies, such as immunotherapy, can be effective for some patients, but they have n...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-03-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/12222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850058690576515072 |
|---|---|
| author | Ahmed Hassanein Saghir Akhtar |
| author_facet | Ahmed Hassanein Saghir Akhtar |
| author_sort | Ahmed Hassanein |
| collection | DOAJ |
| description |
Type 1 diabetes mellitus (T1DM) is a serious, chronic metabolic and autoimmune disease that affects millions globally. While insulin administration remains the most effective treatment, it is not a cure. Long-term therapies, such as immunotherapy, can be effective for some patients, but they have notable limitations and do not provide a permanent solution. As a result, current research has shifted towards stem cell-based therapies, which offer a potentially expandable and scalable source of pancreatic beta cells. These therapies aim to restore long-term endogenous β-cell function in all T1DM patients, provided they can avoid immune recognition and rejection by the host. In this review, we will discuss the latest first-in-human successes of stem cell therapies for T1DM. We will then explore stem cell-derived islet encapsulation technologies and hypoimmune stem cells, examining how they might overcome the need for immunosuppressive therapy. Additionally, we will provide a summary of recent and ongoing biopharmaceutical industry pipelines and clinical trials for stem cell therapies aimed at treating T1DM. These advances suggest that stem cell therapies offer a promising and highly effective approach to treating patients with this chronic disease. However, large-scale clinical trials over the long term are necessary to verify these early successes and assess the curative potential of stem cell therapy for T1DM.
|
| format | Article |
| id | doaj-art-7aeefb87ccc44587b3dbae31212a0fb3 |
| institution | DOAJ |
| issn | 2831-0896 2831-090X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj-art-7aeefb87ccc44587b3dbae31212a0fb32025-08-20T02:51:04ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-03-0110.17305/bb.2025.12222Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the futureAhmed Hassanein0https://orcid.org/0009-0009-0912-5858Saghir Akhtar1https://orcid.org/0000-0003-3177-946XCollege of Medicine, QU Health, Qatar University, Doha, QatarCollege of Medicine, QU Health, Qatar University, Doha, Qatar Type 1 diabetes mellitus (T1DM) is a serious, chronic metabolic and autoimmune disease that affects millions globally. While insulin administration remains the most effective treatment, it is not a cure. Long-term therapies, such as immunotherapy, can be effective for some patients, but they have notable limitations and do not provide a permanent solution. As a result, current research has shifted towards stem cell-based therapies, which offer a potentially expandable and scalable source of pancreatic beta cells. These therapies aim to restore long-term endogenous β-cell function in all T1DM patients, provided they can avoid immune recognition and rejection by the host. In this review, we will discuss the latest first-in-human successes of stem cell therapies for T1DM. We will then explore stem cell-derived islet encapsulation technologies and hypoimmune stem cells, examining how they might overcome the need for immunosuppressive therapy. Additionally, we will provide a summary of recent and ongoing biopharmaceutical industry pipelines and clinical trials for stem cell therapies aimed at treating T1DM. These advances suggest that stem cell therapies offer a promising and highly effective approach to treating patients with this chronic disease. However, large-scale clinical trials over the long term are necessary to verify these early successes and assess the curative potential of stem cell therapy for T1DM. https://www.bjbms.org/ojs/index.php/bjbms/article/view/12222Type 1 diabetes mellitusT1DMstem cellsencapsulationimmunosuppressionpancreatic beta cells |
| spellingShingle | Ahmed Hassanein Saghir Akhtar Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future Biomolecules & Biomedicine Type 1 diabetes mellitus T1DM stem cells encapsulation immunosuppression pancreatic beta cells |
| title | Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future |
| title_full | Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future |
| title_fullStr | Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future |
| title_full_unstemmed | Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future |
| title_short | Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future |
| title_sort | recent advances in stem cell based therapies for type 1 diabetes a glimpse into the future |
| topic | Type 1 diabetes mellitus T1DM stem cells encapsulation immunosuppression pancreatic beta cells |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/12222 |
| work_keys_str_mv | AT ahmedhassanein recentadvancesinstemcellbasedtherapiesfortype1diabetesaglimpseintothefuture AT saghirakhtar recentadvancesinstemcellbasedtherapiesfortype1diabetesaglimpseintothefuture |